Radiopharmaceuticals

University of Melbourne
#Financing #Radiopharmaceuticals #Spinout #Start-ups #University of Melbourne

Melbourne radiopharmaceuticals spinout launches with AUD$12 million

Australian radiopharmaceuticals spinout, Skopos Bio, has launched with an AUD$12 million (US$8.3 million) seed round, led by a global investor syndicate.  The company was founded by three clinical and translational scientists from Melbourne’s Peter MacCallum Cancer Centre (Peter Mac), who continue to treat patients and lead research:  Professor Michael Hofman… Read More

#Business & Investment #News #Start-up Zone

Radiopharmaceutical
#Collaboration #Radiopharmaceuticals #Ratio Therapeutics #RayzeBio

Ratio Therapeutics and RayzeBio advance novel radiopharmaceuticals

Ratio Therapeutics and RayzeBio have entered into a research collaboration and license agreement to advance a novel radiopharmaceutical programme focused on two undisclosed targets.  Under the terms of the agreement, Ratio will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as… Read More

#Business & Investment #News

Tumour microenvironment
#Akiram Therapeutics #Cancer research #Drug development #Radionuclide therapy #Radiopharmaceuticals #Solid tumours

Partnership supports radiopharmaceutical solid tumour development

Akiram Therapeutics has signed an agreement with ITM for the supply of non-carrier-added lutetium-177 (n.c.a. Lu-177) to support the ongoing clinical trial of AKIR001, its lead radiopharmaceutical candidate for the treatment of solid tumours. Lu-177 is one of the most widely used medical radioisotopes in targeted radionuclide therapy and serves… Read More

#News

Radioactive containers
#Oncoinvent #Oncology #Phase I trial #Radiopharmaceuticals

Radiotherapeutic study shows low exposure to healthy organs

Radiopharmaceuticals company Oncoinvent has announced the publication of clinical dosimetry data for Radspherin in ovarian and colorectal cancer in the Journal of Nuclear Medicine.  The publication reports results from nine patients enrolled in the dosimetry cohorts of the Phase I Radspherin studies, which… Read More

#Cancer Research #News

Radiopharmaceutical drug
#European Medicines Agency #Oncology #Orphan drugs #Perspective Therapeutics #Radiopharmaceuticals

Perspective receives European orphan medicinal product designation

Radiopharmaceuticals company Perspective Therapeutics has received orphan medicinal product designation from the European Commission (EC) for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).  The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).  “Patients with unresectable or metastatic… Read More

#Cancer Research #News #Regulatory

#Cancer research #Medicines Discovery Catapult #Nuclear medicine #Radiopharmaceuticals #UK

Is the UK set to become a radiopharma leader?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Dr Juliana Maynard, Head of Translational Imaging at Medicines Discovery Catapult. MDC recently announced a partnership with the UK National Nuclear Lab, and Maynard’s… Read More

#Cancer Research #Featured Podcasts #Podcasts

Cancer research
#Antibody drug conjugate (ADC) #Cancer research #CAR T-cell therapy #KRAS #Radiopharmaceuticals

New tactics against hard-to-treat cancers

It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics.  New modalities, like radiopharmaceuticals, alongside new drug targets, like KRAS mutations, are resulting in therapies that… Read More

#Cancer Research #Exclusive Content

#Drug discovery #Oncology #RadioMedix #Radiopharmaceuticals

The challenges and advancements in radiopharmaceuticals

DDW Editor Reece Armstrong speaks to Dr Ebrahim Delpassand, CEO of RadioMedix, about scaling access to radiopharmaceuticals and the company’s attempt to innovate in hard-to-treat cancers. RA: Could you discuss RAHA-100 and your goal of democratising access to the 212Pb isotope – why is this important?    ED: One of the central challenges in radiopharmaceutical targeted alpha therapy… Read More

#Exclusive Content

#Collaboration #Radiopharmaceuticals #Regeneron Pharmaceuticals #Telix Pharmaceuticals

Regeneron & Telix collaborate on next-gen radiopharmaceuticals

Pharmaceutical companies Regeneron and Telix have announced a collaboration to develop and commercialise next generation radiopharmaceutical therapies. The collaboration will include multiple solid tumour targets from Regeneron’s portfolio of antibodies. The companies also aim to develop radio-diagnostics to support patient selection and treatment response assessment. The deal will see Telix… Read More

#Business & Investment #News

Map of China
#China #Radiopharmaceuticals

Radspherin receives patent protection in China 

The China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin, a radiopharmaceutical treating micrometastases in cancer patients.  Radspherin, developed by biotechnology company Oncoinvent, is a receptor-independent alpha radiation therapy that destroys residual micrometastases using a single, highly localised dose of alpha radiation.  … Read More

#News

Theranostic radiopharmaceuticals
#Drug discovery #Radiopharmaceuticals

New protein drugs could pave way for faster drug development 

A new class of protein drugs have shown amenability to multiple isotopes, paving the way for faster radiopharmaceutical drug development.  Biotechnology company Molecular Partners announced preclinical data showing its Radio-DARPins are suitable to different isotopes, each specific for a different tumour target.   DARPin (Designed Ankyrin Repeat Protein)… Read More

#News

Theranostic radiopharmaceuticals
#Aptamer Group #Biotech #Radiopharmaceuticals

Radiopharmaceutical programme to develop therapeutic targets 

Biotechnology company Aptamer Group has launched a radiopharmaceutical programme to develop new therapeutic targets.  The programme, launched in collaboration with Radiopharmium, will look to develop three strategic therapeutic targets across high-value clinical indications.  The targets were identified through Aptamer’s Optimer platform and will now be progressed through in vitro… Read More

#News

#Cancer research #Nuclear medicine #Radiopharmaceuticals #UK

UK project to develop ‘cutting edge’ radiopharmaceuticals 

A £19 million ($25 million) UK programme is set to power the recycling of nuclear materials to develop cutting edge treatments for cancer.  Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create… Read More

#Cancer Research #News

FDA headquarters
#FDA #Haematology #Oncology #Pentixapharm #Radiopharmaceuticals

FDA approves Pentixapharm’s dual theranostic INDs

The US Food and Drug Administration (FDA) has approved a clinical study of Pentixapharm’s CXCR4-targeted theranostic programme in haemato-oncology, following a 30-day safety review of two Investigational New Drug (IND) applications.  The two IND submissions support the single PENTHERA Phase I/II protocol, which evaluates the combined use of PentixaFor imaging… Read More

#News #Regulatory

Theranostic radiopharmaceuticals
#Affibody #Radiopharmaceuticals #Sweden

Affibody secures SEK 307m with fully guaranteed rights issue 

Swedish radiopharmaceuticals company Affibody Medical has secured SEK 307 million ($34 million) by carrying out a fully guaranteed rights issue.  Affibody’s main shareholder Patricia Industries, part of Investor AB, has via its subsidiary Duba AB committed to subscribe for its pro rata share, as well as any remaining shares not subscribed… Read More

#Business & Investment #News

#Actithera #AstraZeneca #Radiopharmaceuticals

Actithera appoints new CMO to advance radiopharmaceuticals 

Radiopharmaceutical biotech company Actithera has appointed Darshan Dalal as Chief Medical Officer.  Dalal will lead the clinical strategy and build the clinical development organisation as Actithera advances its lead fibroblast activation protein (FAP)-targeting RLT into the clinic. The company is also building its pipeline of differentiated precision-engineered radiopharmaceuticals.  Dalal… Read More

#News